Introduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma

No abstract available
Source: The Cancer Journal - Category: Cancer & Oncology Tags: Review Articles Source Type: research

Related Links:

This article summarizes the milestones in the development of selinexor leading to this first approval for RRMM.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 7 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Deepu Madduri, Madhav V. Dhodapkar, Sagar Lonial, Sundar Jagannath, Hearn Jay ChoAbstractTherapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with the immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T-cell–directed strategies designed to promote cytotoxic activity a...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilization of these drugs in the real world. All current reported data on monoclonal antibodies is from clinical trials, without any real-world experience. Patients from Mayo Clinic Florida or Arizona diagnosed with relapsed or refractory multiple myeloma who were treated with Daratumumab or Elotuzumab alone or in combination between 1 January 2016 and 31 December 2016 were included in the analysis. Daratumumab-treated patients (n = 78...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Papers Source Type: research
Blood Cancer Journal, Published online: 16 August 2019; doi:10.1038/s41408-019-0232-6Oprozomib in patients with newly diagnosed multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
lo Alberto Zaniboni The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequent risk of cancer. We included observational studies of adult subjects with previous exposure to antibiotics and available information on incident cancer diagnoses. For each of the eligible studies, data we...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Rockville-based CASI Pharmaceuticals Inc. has earned approval in China to market a cancer therapy — its first commercial product in its nearly three decades of existence. The biopharmaceutical company has received clearance from the China National Medical Products Administration, China’s regulatory agency for drugs and medical devices, to launch an injection treatment for patients with mult iple myeloma, a blood cancer that forms in infection-fighting plasma cells. It’s a major milestone for…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia &Lymphoma Society to look at changes in the DNA sequence that affects the development and advancement of multiple myeloma.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news
Rockville-based CASI Pharmaceuticals Inc. has earned approval in China to market a cancer therapy — its first commercial product in its nearly three decades of existence. The biopharmaceutical company has received clearance from the China National Medical Products Administration, China’s regulatory agency for drugs and medical devices, to launch an injection treatment for patients with mult iple myeloma, a blood cancer that forms in infection-fighting plasma cells. It’s a major milestone for…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
CONCLUSION: Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape. PMID: 31407112 [PubMed - as supplied by publisher]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
Blood Cancer Journal, Published online: 12 August 2019; doi:10.1038/s41408-019-0224-6Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Myeloma